Ser1911
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser1911  -  FREM3 (human)

Site Information
LLIPVRRsGDAsQEL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 6152622

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 )
Disease tissue studied:
lung cancer ( 1 ) , non-small cell squamous cell lung carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
rapamycin ( 1 )

References 

1

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

2

Moritz A (2009) CST Curation Set: 5891; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info